human
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['The prevalence of iron deficiency in pediatric sickle cell disease (SCD) is difficult to describe because standard markers of iron metabolism are altered in this inflammatory state. Soluble transferrin receptor (sTfR) is an alternative marker of iron utilization. Our primary objective was to evaluate the utility of sTfR as a biomarker of hemolysis and erythropoietic drive versus iron metabolism in SCD.', 'In a prospective cohort study, we screened 51 children with SCD at steady state with markers of iron status and sTfR. Iron deficient patients were treated with ferrous sulfate for 6 weeks, followed by repeat testing.', "At baseline, there was stronger correlation between sTfR and markers of hemolysis and erythropoietic drive, including hemoglobin (Spearman's r = -0.67, P < or = 0.001) and reticulocyte count (Spearman's r = 0.59, P < or = 0.001), than with markers of iron metabolism, such as transferrin saturation (TS; Spearman's r = 0.33, P = 0.02) and ferritin (Spearman's r = 0.17, P = 0.26). Eleven (21%) of the 51 children were identified as iron deficient. For treated patients, response to iron therapy was variable, although all patients had a significant increase (mean 11 +/- 3.9%, P = 0.001) in TS."] Do elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease?
OUTPUT:

agent
yes
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['The prevalence of iron deficiency in pediatric sickle cell disease (SCD) is difficult to describe because standard markers of iron metabolism are altered in this inflammatory state. Soluble transferrin receptor (sTfR) is an alternative marker of iron utilization. Our primary objective was to evaluate the utility of sTfR as a biomarker of hemolysis and erythropoietic drive versus iron metabolism in SCD.', 'In a prospective cohort study, we screened 51 children with SCD at steady state with markers of iron status and sTfR. Iron deficient patients were treated with ferrous sulfate for 6 weeks, followed by repeat testing.', "At baseline, there was stronger correlation between sTfR and markers of hemolysis and erythropoietic drive, including hemoglobin (Spearman's r = -0.67, P < or = 0.001) and reticulocyte count (Spearman's r = 0.59, P < or = 0.001), than with markers of iron metabolism, such as transferrin saturation (TS; Spearman's r = 0.33, P = 0.02) and ferritin (Spearman's r = 0.17, P = 0.26). Eleven (21%) of the 51 children were identified as iron deficient. For treated patients, response to iron therapy was variable, although all patients had a significant increase (mean 11 +/- 3.9%, P = 0.001) in TS."] Do elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease?
OUTPUT:
